Introduction
============

The prevalence of metabolic syndrome (Mets), which is defined as obesity with hypertension or glucose intolerance, has been increasing worldwide and varies from 12-41% ([@b1-br-0-0-1242]). Several studies demonstrated that moderate alcohol consumption reduces the risk of Mets-related diseases and mortality ([@b2-br-0-0-1242]). Light or moderate alcohol consumption is reported to enhance insulin sensitivity, increase high-density lipoprotein cholesterol (HDL-C) and reduce the risk of type 2 diabetes mellitus ([@b9-br-0-0-1242]). Moreover, non-alcoholic fatty liver disease (NAFLD) is considered a phenotype of Mets in the liver ([@b10-br-0-0-1242]). According to previous studies in Japan, the prevalence of NAFLD in the general population ranges from 24.6-29.7% ([@b13-br-0-0-1242],[@b14-br-0-0-1242]) and light or moderate alcohol consumption is negatively associated with fatty liver ([@b15-br-0-0-1242]). Previously, chronic kidney disease (CKD) has been considered a renal phenotype of Mets ([@b20-br-0-0-1242]). Previous studies reported that light or moderate alcohol consumption reduced the risk of CKD ([@b21-br-0-0-1242],[@b22-br-0-0-1242]). Elevated serum uric acid has been proposed as a risk factor for not only CKD ([@b23-br-0-0-1242]) but also diabetes ([@b24-br-0-0-1242]) and hypertension ([@b25-br-0-0-1242]). While alcohol consumption has been recognized as an important risk factor for gout and hyperuricemia, moderate alcohol consumption does not increase the risk of hyperuricemia ([@b26-br-0-0-1242],[@b27-br-0-0-1242]). However, certain studies reported that even light alcohol consumption (LAC) could increase blood pressure in Japanese men ([@b28-br-0-0-1242]).

Recently, liver dysfunction and hypercholesterolemia have been reported as the most common abnormal findings associated with Mets among individuals who underwent a regular health check-up in Japan. The main reason for the increase in liver dysfunction is associated with the increasing incidence of NAFLD ([@b31-br-0-0-1242]). Although there have been some reports on the effect of LAC on Mets-related diseases in individuals with NAFLD, the association between LAC and each Mets-related disease among those with or without fatty liver is unclear. Therefore, this study investigated the effect of LAC on Mets-related diseases, such as obesity, dyslipidemia, impaired glucose tolerance (IGT), hyperuricemia and CKD, in individuals with and without fatty liver.

Patients and methods
====================

### Subjects

In this cross-sectional study, 2,096 men who underwent regular health check-up, including physical and physiological examinations, abdominal ultrasound, and blood screening examination, between January 2017 and December 2017 at Fukuchiyama City Hospital (Fukuchiyama City, Japan) were enrolled. Subjects were included if they fulfilled the following criteria: Absence of markers of hepatitis B surface antigen and hepatitis C antibody, alcohol consumption ≥20 g/day, and chronic liver diseases, including autoimmune hepatitis, primary biliary cholangitis, and drug-induced liver disease. Patients judged to be inappropriate for this study were excluded (n=906). A total of 1,190 eligible subjects were analyzed. Patient characteristics are shown in [Table I](#tI-br-0-0-1242){ref-type="table"}. All patients provided written informed consent prior to participation and the study was conducted in accordance with the Declaration of Helsinki and was approved by the institutional review board of Fukuchiyama City Hospital.

### Physical examination and serum biochemistry

The subjects were divided into two groups: Fatty liver group and non-fatty liver group. Body weight and height were obtained for both groups, and body mass index (BMI) was calculated. Waist circumference (WC) was measured at the level of the umbilicus according to the definition in the Japanese Committee for the Diagnostic Criteria of Metabolic Syndrome ([@b32-br-0-0-1242]). Venous blood samples (10 ml) were obtained from all subjects following a 12-h overnight fast. Aspartate aminotransferase, alanine aminotransferase, γ-glutamyl transpeptidase (GGT), total cholesterol, HDL-C, triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), uric acid (UA), fasting plasma glucose (FPG), hemoglobin A1c (HbA1c; National Glycohemoglobin Standardization Program) and estimated glomerular filtration rate (eGFR) were measured using standard clinical chemistry laboratory techniques.

### Assessment of fatty liver

All the subjects received an abdominal ultrasound to assess fatty liver. Experienced technicians performed real-time ultrasonography to detect vascular blurring, deep attenuation and increased liver echotexture in comparison to the kidneys (liver-kidney contrast) to assess fatty infiltration ([@b33-br-0-0-1242]). Each certificated gastroenterologist independently reviewed the images and judged that the presence of one or more findings was indicative of a fatty liver.

### Evaluation of alcohol consumption

Lifestyle-related information, such as medical history, smoking status and alcohol consumption, was obtained using a common standardized self-response questionnaire. The amount of alcohol consumption per day was calculated in grams using the representative percentage of alcohol by volume of each type of alcohol beverage. Subjects were classified into two groups according to drinking information: Non-drinkers and light drinkers; the latter is defined as those who consumed \>0 to \<20 g of alcohol per day.

### Variables

Obesity was defined as BMI ≥25 kg/m^2^, which is the commonly used definition of obesity in the Japanese population ([@b34-br-0-0-1242]). Hypertension was defined as systolic blood pressure (SBP) ≥140 mmHg, diastolic blood pressure (DBP) ≥90 mmHg, or the use of medications for hypertension. Dyslipidemia was defined as TG ≥150 mg/dl, HDL-C \<40 mg/dl and LDL-C ≥140 mg/dl or the use of medications for dyslipidemia. IGT was defined as FPG ≥110 mg/dl or the use of medications for diabetes mellitus. Hyperuricemia was defined as UA \>7.0 mg/dl or the use of medications for hyperuricemia. CKD was defined as eGFR \<60 ml/min/1.73 m^2^ and/or overt proteinuria ([@b35-br-0-0-1242]). According to the Japanese criteria, Mets is defined as WC ≥85 cm and the presence of two or more of the following risk factors: SBP ≥130 mmHg or DBP ≥85 mmHg; reduced HDL-C (HDL-C \<40 mg/dl) and/or increased TG (TG ≥150 mg/dl); and FPG ≥110 mg/dl.

### Statistical analysis

Baseline data were expressed as median with interquartile range and subject number (%) for categorical variables. P-values were calculated using a Mann-Whitney U test for continuous variables and Fisher\'s exact probability test or the Chi square test for categorical variables. Factors with a significant influence on the prevalence of hypertension in the non-fatty liver group were determined by univariate analysis. Age, obesity, dyslipidemia, IGT, hyperuricemia, CKD, smoking and LAC were subsequently subjected to multivariable logistic regression analyses. P\<0.05 was considered to indicate a statistically significant difference. IBM SPSS version 16.0 for Windows (SPSS, Inc.) was used in the statistical analyses.

Results
=======

### Clinical characteristics of non-drinkers and light drinkers

The protocol followed for participant selection and enrollment is shown in [Fig. 1](#f1-br-0-0-1242){ref-type="fig"}. Of the 2,096 participants, 906 were excluded. Of the 1,190 participants included in the analysis, 505 (42.4%) were non-drinkers and 685 (57.6%) were light drinkers. [Table I](#tI-br-0-0-1242){ref-type="table"} shows the comparison of the clinical characteristics between non-drinkers and light drinkers. No significant difference was noted between non-drinkers and light drinkers in terms of age and BMI. TG, LDL, HbA1c and the prevalence of proteinuria were significantly decreased in light drinkers compared with in non-drinkers (P\<0.01). DBP, HDL, GGT, and Fib-4 index were significantly increased in light drinkers compared with in non-drinkers (P\<0.05). No significant difference was observed between non-drinkers and light drinkers in the prevalence of hypertension and hyperuricemia. The prevalence of obesity, dyslipidemia, IGT, fatty liver, CKD and Mets, according to the Japanese criteria, was significantly decreased in light drinkers compared with in non-drinkers (P\<0.05); in fact, this prevalence was lowest in light drinkers among the 4 groups of participants (non-drinkers; light drinkers, alcohol use/day \<20 g; moderate drinkers, alcohol use/day 20-59 g; heavy drinkers, alcohol use/day ≥60 g; [Table SI](#SD1-br-0-0-1242){ref-type="supplementary-material"}). Among the lifestyle parameters, regular exercise habit was significantly more prevalent in light drinkers than in non-drinkers (P\<0.05), but no significant difference was noted between non-drinkers and light drinkers in terms of current smoking.

### Treatment for each Mets-related diseases in non-drinkers and light drinkers

A comparison of the treatment for each Mets-related disease between non-drinkers and light drinkers is shown in [Table II](#tII-br-0-0-1242){ref-type="table"}. No significant difference in the treatment for hypertension was observed between non-drinkers and light drinkers. DBP in those without treatment for hypertension was significantly increased in light drinkers compared with in non-drinkers (P\<0.01). No significant difference in the treatment for dyslipidemia was noted between non-drinkers and light drinkers. Regardless of treatment for dyslipidemia, HDL was significantly increased in light drinkers compared with in non-drinkers (P\<0.001). TG and HDL levels in those without treatment for dyslipidemia were significantly decreased in light drinkers compared with those in non-drinkers. The number of subjects receiving treatment for IGT was significantly decreased among light drinkers compared with among non-drinkers (P\<0.05). No significant difference was found in the treatment for hyperuricemia between non-drinkers and light drinkers.

### Prevalence of Mets-related diseases and risk factors between non-drinkers and light drinkers

A comparison of the prevalence of each risk factor for Mets-related diseases between non-drinkers and light drinkers in the non-fatty liver and fatty liver groups are shown in [Table III](#tIII-br-0-0-1242){ref-type="table"}. In the non-fatty liver group, no significant difference was found in age and BMI between non-drinkers and light drinkers. The prevalence of hypertension was significantly increased in light drinkers compared with in non-drinkers (P\<0.05; [Table III](#tIII-br-0-0-1242){ref-type="table"}). In the fatty liver group, no significant difference was observed in age and BMI between non-drinkers and light drinkers. The prevalence of dyslipidemia, IGT and Mets by the Japanese criteria was significantly decreased in light drinkers than in non-drinkers (P\<0.05; [Table III](#tIII-br-0-0-1242){ref-type="table"}).

### Odds ratio for each Mets-related diseases comparing light drinkers to non-drinkers

The odds ratio \[OR; 95% confidence interval (CI), P-value\] for each Mets-related disease in light drinkers and non-drinkers is shown in [Fig. 2](#f2-br-0-0-1242){ref-type="fig"}. In the non-fatty liver group, the OR for hypertension among light drinkers was 1.73 (1.04-2.88, P=0.035). In the fatty liver group, the OR for each Mets-related disease among light drinkers were as follows: Dyslipidemia, 0.64 (0.44-0.95, P=0.028); IGT, 0.57 (0.37-0.88, P=0.012); CKD, 0.58 (0.36-0.94, P=0.029) and Mets by the Japanese criteria, 0.63 (0.44-0.92, P=0.016).

Discussion
==========

In this cross-sectional study, the results indicated that the effect of LAC was different between individuals with and those without fatty liver. In the non-fatty liver group, the prevalence of hypertension in light drinkers was 35.3%, which was increased compared with in non-drinkers (26.6%). In the fatty liver group, the prevalence of dyslipidemia, IGT, CKD and Mets by the Japanese criteria was lower in light drinkers than that in non-drinkers.

Fatty liver among non-drinkers and light drinkers was diagnosed as NAFLD, which is considered a phenotype of Mets in the liver ([@b10-br-0-0-1242]). Previous studies reported that light or moderate alcohol consumption is negatively associated with fatty liver ([@b15-br-0-0-1242]). The mechanism of inverse association of alcohol consumption with fatty liver has been previously elucidated. Moderate alcohol consumption has been shown to reduce fasting serum insulin and TG levels and is associated with a lower incidence of diabetes, all of which are important risk factors for the development of NAFLD ([@b2-br-0-0-1242],[@b36-br-0-0-1242]). In addition, certain studies revealed that the level of adiponectin, which is a hormone involved in lipid and glucose homeostasis and is reduced in patients with NAFLD, is upregulated in people who consume alcohol ([@b37-br-0-0-1242]). Antioxidant agents in alcoholic beverages, mostly in wine ([@b15-br-0-0-1242]), may also exert a protective effect in NAFLD. In this study, the serum levels of TG, LDL and HbA1c were lower, and the prevalence of IGT and fatty liver was decreased in light drinkers compared with in non-drinkers.

The relationship between alcohol consumption and all-cause mortality has been reported to have J- or U-shaped curve ([@b8-br-0-0-1242]). This effect is thought to be mainly because of reduction in cardiovascular disease ([@b40-br-0-0-1242],[@b41-br-0-0-1242]), which can be attributed to the beneficial effect of alcohol on plasma lipids levels, hemostatic factors ([@b2-br-0-0-1242],[@b41-br-0-0-1242]) and insulin sensitivity ([@b36-br-0-0-1242]). Several studies have shown the influence of lifestyle factors on better mortality in moderate drinkers. Moderate alcohol users tend to have higher socioeconomic status, high level of education, increased physical activity and less obesity ([@b42-br-0-0-1242],[@b43-br-0-0-1242]). The prevalence of subjects with regular exercise habit was greater in light drinkers in the present study.

Moreover, the present study indicated that in all subjects, the prevalence of obesity, dyslipidemia, IGT, fatty liver, CKD and Mets by the Japanese criteria was decreased among light drinkers compared with among non-drinkers. These results agreed with those of previous reports ([@b2-br-0-0-1242],[@b15-br-0-0-1242],[@b36-br-0-0-1242],[@b37-br-0-0-1242],[@b40-br-0-0-1242]). In the non-fatty liver group, because the prevalence of Mets-related diseases was low, no significant relationship between LAC and the prevalence of Mets-related diseases without hypertension was observed. In the fatty liver group, a relationship between LAC and lower prevalence of dyslipidemia, IGT, CKD and Mets by the Japanese criteria was observed. The inverse association between LAC and the prevalence of dyslipidemia, IGT, CKD, and Mets by the Japanese criteria may be explained by an improvement in insulin sensitivity and other metabolic parameters, including improved cytokine profiles and decreased oxidative stress, as has been described in the general population ([@b8-br-0-0-1242],[@b12-br-0-0-1242],[@b30-br-0-0-1242],[@b44-br-0-0-1242],[@b45-br-0-0-1242]). NAFLD is considered a phenotype of Mets in the liver ([@b10-br-0-0-1242]) and in the fatty liver group, the prevalence of each Mets-related disease was actually increased compared with in the non-fatty liver group in this study. Thus, the effect of LAC to suppress Mets-related diseases has been shown more clearly in the fatty liver group.

Nonetheless, numerous studies have shown that alcohol consumption is associated with increased blood pressure. Furthermore, increased alcohol consumption affects endothelial function ([@b40-br-0-0-1242],[@b46-br-0-0-1242]). Oda *et al* ([@b30-br-0-0-1242]) reported that light to moderate alcohol consumption impairs endothelial function. Endothelial dysfunction is the initial stage in the pathogenesis of atherosclerosis and plays an important role in the development of atherosclerosis and hypertension. The present study indicated that the prevalence of hypertension is increased in light drinkers compared with in non-drinkers, especially in the non-fatty liver group. While it may suppress fatty liver, LAC may promote hypertension. Increased caloric intake through consuming alcoholic beverages and elevated salt intake associated with drinking may also be involved in alcohol-related hypertension ([@b47-br-0-0-1242]). Taking into consideration that liver dysfunction is the most common abnormal finding associated with Mets in a regular health check-up ([@b31-br-0-0-1242]), hypertension could occur in Mets-related diseases first. Moreover, in the fatty liver group, no significant relationship between LAC and hypertension was found. VanWagner *et al* ([@b48-br-0-0-1242]) reported that alcohol use may not reduce the risk of cardiovascular disease in patients with NAFLD. A previous study also demonstrated that alcohol use is not associated with a significant difference in markers of subclinical atherosclerosis, such as coronary artery calcium, which is a well-established risk marker for future cardiovascular events ([@b49-br-0-0-1242]).

This study has some limitations. Eating habits, which may have an influence on Mets-related diseases and the types of beverages consumed were not evaluated. Selection bias was also possible. Most of the participants were healthy and willing to undergo medical check-up. Further studies are needed to address these limitations.

In conclusion, the present study found that the effect of LAC was different between individuals with and those without fatty liver. In the non-fatty liver group, LAC may increase the risk of hypertension, whereas in the fatty liver group, LAC may decrease the prevalence of dyslipidemia, IGT, CKD and Mets by the Japanese criteria. The effect of LAC to suppress Mets-related diseases has been shown more clearly in the fatty liver group, because of the higher prevalence of each Mets-related disease. On the other hand, it may suppress fatty liver and LAC may promote hypertension.
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###### 

Comparison of clinical characteristics between non-drinkers and light drinkers.

  Characteristics             Non-drinker (n=505)   Light drinker (n=685)   P-value
  --------------------------- --------------------- ----------------------- ---------
  Age (years)                 56 (28-83)            56 (24-78)              0.920
  BMI (kg/m^2^)               23.6 (15.2-52.9)      23.3 (16.0-41.4)        0.150
  WC (cm)                     85.5 (61.0-143.0)     85.0 (63.0-127.0)       0.080
  Obesity                     174 (34.4)            195 (28.3)              0.020
  SBP (mmHg)                  126 (93-196)          128 (94-190)            0.212
  DBP (mmHg)                  79 (48-122)           81 (54-112)             0.028
  Hypertension                200 (39.6)            298 (43.3)              0.194
  T-CHO (mg/dl)               197 (86-330)          195 (106-312)           0.769
  TG (mg/dl)                  104 (18-772)          93 (28-648)             0.009
  HDL (mg/dl)                 50 (26-93)            54 (27-100)             \<0.001
  LDL (mg/dl)                 123 (33-228)          119 (47-229)            0.007
  Dyslipidemia                296 (58.6)            329 (47.8)              \<0.001
  FPG (mg/dl)                 98 (74-284)           98 (76-291)             0.149
  HbA1c (NGSP) (%)            5.9 (4.6-12.0)        5.8 (4.9-11.1)          0.016
  IGT                         119 (23.5)            117 (17.0)              0.006
  UA (mg/dl)                  5.8 (0.9-11.1)        6.0 (0.9-9.6)           0.076
  Hyperuricemia               106 (20.9)            148 (21.6)              0.798
  AST (IU/l)                  21 (12-64)            22 (12-124)             0.094
  ALT (IU/l)                  22 (6-108)            21 (9-148)              0.314
  GGT (IU/l)                  26 (9-202)            30 (9-737)              0.001
  Fib-4 index                 1.07 (0.29-3.96)      1.16 (0.35-3.86)        0.027
  Fatty liver                 269 (53.7)            292 (42.8)              \<0.001
  eGFR (ml/min/1.73 m^2^)     75.7 (12.2-151.5)     75.8 (40.9-136.1)       0.644
  Proteinuria                 41 (8.1)              32 (4.6)                0.014
  CKD                         91 (18.0)             89 (12.9)               0.017
  Mets by Japanese criteria   145 (28.7)            144 (20.9)              0.002
  Regular exercises           109 (21.5)            192 (28.0)              0.011
  Current smoking             99 (19.6)             124 (18.1)              0.512

Results are presented as n (%) for qualitative data or as median (range) for quantitative data. Light drinker, 0-19 g alcohol/day. AST, aspartate aminotransferase; ALT, alanine aminotransferase; BMI, body mass index; CKD, chronic kidney disease; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; FPG, fasting plasma glucose; GGT, γ-glutamyl transpeptidase; HbA1c, hemoglobin A1c; HDL, high-density lipoprotein; IGT, impaired glucose tolerance; LDL, low-density lipoprotein; Mets, metabolic syndrome; NGSP, National Glycohemoglobin Standardization Program; SBP, systolic blood pressure; T-CHO, total cholesterol; TG, triglycerides; UA, uric acid; WC, waist circumference.

###### 

Comparison between non- and light drinkers receiving treatment for Mets-associated diseases.

  A, Hypertension                                                       
  ----------------------- --------------------- ----------------------- ---------
  Treatment               119 (23.6)            159 (23.2)              0.887
       SBP (mmHg)         132 (101-179)         132 (94-170)            0.383
       DBP (mmHg)         83 (54-111)           83 (54-109)             0.404
  Treatment (-)           386 (76.4)            526 (76.8)               
       SBP (mmHg)         123 (96-196)          126 (94-190)            0.068
       DBP (mmHg)         78 (48-122)           81 (56-112)             0.003
  B, Dyslipidemia                                                       
  Characteristics         Non-drinker (n=505)   Light drinker (n=685)   P-value
  Treatment (+)           101 (20.0)            108 (15.7)              0.058
       T-CHO (mg/dl)      185 (114-330)         181 (128-293)           0.894
       TG (mg/dl)         113 (42-772)          100 (42-304)            0.310
       HDL (mg/dl)        49 (26-77)            54 (31-93)              0.004
       LDL (mg/dl)        110 (46-228)          105 (61-203)            0.105
  Treatment (-)           404 (80.0)            577 (74.3)               
       T-CHO (mg/dl)      202 (86-300)          198 (106-312)           0.484
       TG (mg/dl)         101 (18-687)          91 (28-648)             0.028
       HDL (mg/dl)        51 (27-93)            54 (27-100)             \<0.001
       LDL (mg/dl)        126 (33-202)          121 (47-229)            0.006
  C, IGT                                                                
  Characteristics         Non-drinker (n=505)   Light drinker (n=685)   P-value
  Treatment (+)           44 (8.7)              38 (5.5)                0.033
       FPG (mg/dl)        130 (83-84)           134 (87-220)            0.649
       HbA1c (NGSP) (%)   7.0 (5.0-12.0)        6.8 (6.1-10.8)          0.666
  Treatment (-), n (%)    461 (91.3)            647 (94.5)               
       FPG (mg/dl)        98 (74-156)           97 (76-291)             0.360
       HbA1c (NGSP) (%)   5.8 (4.6-8.4)         5.7 (4.9-11.1)          0.051
  D, Hyperuricemia                                                      
  Characteristics         Non-drinker (n=505)   Light drinker (n=685)   P-value
  Treatment (+)           30 (5.9)              52 (7.6)                0.229
       UA (mg/dl)         6.2 (4.3-7.9)         6.5 (3.6-8.7)           0.296
  Treatment (-), n (%)    475 (94.1)            632 (92.4)               
       UA (mg/dl)         5.8 (0.9-11.1)        6.0 (0.6-9.6)           0.148

Results are presented as n (%) for qualitative data or as median (range) for quantitative data. Light drinker, 0-19 g alcohol/day. DBP, diastolic blood pressure; FPG, fasting plasma glucose; HbA1c, hemoglobin A1c; HDL, high-density lipoprotein; IGT, impaired glucose tolerance; LDL, low-density lipoprotein; Mets, metabolic syndrome; NGSP, National Glycohemoglobin Standardization Program; SBP, systolic blood pressure; T-CHO, total cholesterol; TG, triglycerides; UA, uric acid.

###### 

Comparison of the prevalence of Mets-associated diseases and risk factors between non-drinkers and light drinkers.

  A, Prevalence of Mets-associated diseases and risk factors in the non-fatty liver group                                                 
  ----------------------------------------------------------------------------------------- --------------------- ----------------------- ---------
  Age (years)                                                                               56 (28-83)            56 (24-78)              0.610
  BMI (kg/m^2^)                                                                             21.8 (15.2-31.4)      22.1 (16.1-33.1)        0.060
  Obesity                                                                                   28 (11.8)             53 (13.4)               0.557
  Hypertension                                                                              63 (26.6)             139 (35.3)              0.024
  Dyslipidemia                                                                              106 (44.9)            148 (37.6)              0.073
  IGT                                                                                       27 (11.4)             53 (13.4)               0.456
  Hyperuricemia                                                                             31 (13.1)             61 (15.5)               0.413
  CKD                                                                                       38 (16.1)             49 (12.4)               0.202
  Mets by Japanese criteria                                                                 25 (20.5)             45 (11.4)               0.741
  Regular exercises                                                                         66 (27.9)             128 (32.5)              0.336
  Current smoking                                                                           58 (24.5)             71 (18.0)               0.050
  B, Prevalence of Mets-associated diseases and risk factors in the fatty liver group                                                     
  Characteristic                                                                            Non-drinker (n=269)   Light drinker (n=292)   P-value
  Age (years)                                                                               56 (30-75)            56 (31-76)              0.479
  BMI (kg/m^2^)                                                                             25.2 (19.3-52.9)      24.8 (18.6-41.4)        0.133
  Obesity                                                                                   146 (54.2)            140 (47.9)              0.134
  Hypertension                                                                              137 (50.9)            158 (54.1)              0.451
  Dyslipidemia                                                                              189 (70.2)            179 (61.3)              0.026
  IGT                                                                                       92 (34.2)             64 (21.9)               0.001
  Hyperuricemia                                                                             75 (27.8)             87 (29.2)               0.617
  CKD                                                                                       53 (19.7)             40 (13.6)               0.057
  Mets by Japanese criteria                                                                 120 (44.6)            98 (33.5)               0.007
  Regular exercises                                                                         43 (15.9)             64 (21.9)               0.074
  Current smoking                                                                           41 (15.2)             53 (18.1)               0.357

Results are presented as n (%) for qualitative data or as median (range) for quantitative data. Light drinker, 0-19 g alcohol/day. BMI, body mass index; CKD, chronic kidney disease; IGT, impaired glucose tolerance; Mets, metabolic syndrome.
